Lawrence B. Schwartz

Virginia Commonwealth University (VCU), School of Medicine, Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine

Richmond, VA

United States

SCHOLARLY PAPERS

2

DOWNLOADS

12

CITATIONS

1

Scholarly Papers (2)

1.

An Allosteric Anti-Tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma

Number of pages: 64 Posted: 03 Mar 2019 Last Revised: 29 May 2019
Genentech, Inc. - San Francisco - Departments of Early Discovery Biochemistry, Genentech, Inc. - San Francisco - Immunology Discovery, Genentech, Inc. - San Francisco - Biomarker Discovery OMNI, Genentech, Inc. - San Francisco - Biochemical and Cellular Pharmacology, Genentech, Inc. - San Francisco - Biomarker Discovery OMNI, Genentech, Inc. - San Francisco - Human Genetics, Genentech, Inc. - San Francisco - Bioinformatics, Genentech, Inc. - San Francisco - OMNI Biomarker Development, Genentech, Inc. - San Francisco - Biochemical and Cellular Pharmacology, Genentech, Inc. - San Francisco - Antibody Engineering, Genentech, Inc. - San Francisco - Antibody Engineering, University of California, San Francisco (UCSF), School of Medicine, Department of Medicine, Genentech, Inc. - San Francisco - Biochemical and Cellular Pharmacology, Genentech, Inc. - San Francisco - Departments of Early Discovery Biochemistry, Genentech, Inc. - San Francisco - Biomolecular Resources, Genentech, Inc. - San Francisco - Translational Immunology, Genentech, Inc. - San Francisco - Translational Immunology, Genentech, Inc. - San Francisco - Structural Biology, Genentech, Inc. - San Francisco - Human Genetics, Genentech, Inc. - San Francisco - Human Genetics, Genentech, Inc. - San Francisco - Biomolecular Resources, Genentech, Inc. - San Francisco - Protein Chemistry, Genentech, Inc. - San Francisco - Protein Chemistry, Genentech, Inc. - San Francisco - Protein Chemistry, Genentech, Inc. - San Francisco - Protein Chemistry, Genentech, Inc. - San Francisco - Preclinical and Translational Pharmacokinetics, Genentech, Inc. - San Francisco - Preclinical and Translational Pharmacokinetics, Genentech, Inc. - San Francisco - OMNI Biomarker Development, Virginia Commonwealth University (VCU), School of Medicine, Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Charité - Universitätsmedizin Berlin - Department of Dermatology and Allergy, Genentech, Inc. - San Francisco - Antibody Engineering, Genentech, Inc. - San Francisco - Antibody Engineering, Genentech, Inc. - San Francisco - Antibody Engineering, Genentech, Inc. - San Francisco - Antibody Engineering, Genentech, Inc. - San Francisco - Safety Assessment, Genentech, Inc. - San Francisco - Safety Assessment, Genentech, Inc. - San Francisco - OMNI Biomarker Development, Genentech, Inc. - San Francisco - Translational Immunology, Genentech, Inc. - San Francisco - Departments of Early Discovery Biochemistry, Genentech, Inc. - San Francisco - Immunology Discovery, Genentech, Inc. - San Francisco - OMNI Biomarker Development, Genentech, Inc. - San Francisco - Bioinformatics, Genentech, Inc. - San Francisco - Structural Biology, Genentech, Inc. - San Francisco - Immunology Discovery, Genentech, Inc. - San Francisco - Departments of Early Discovery Biochemistry and Genentech, Inc. - San Francisco - Immunology Discovery
Downloads 8 (590,984)

Abstract:

Loading...

2.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks: An Open-Label Extension Study of the COMPACT Trial

Number of pages: 133 Posted: 27 Sep 2018
Pennsylvania State University - Department of Pediatrics, University of California, San Diego (UCSD) - School of Medicine, Bart's Health NHS Trust - The Royal London Hospital, University of Milan - Department of Biomedical and Clinical Sciences "Luigi Sacco", Johannes Gutenberg University Mainz, Guy's and St Thomas' NHS Foundation Trust - Guy's Hosital (Tower Wing), South Western Sydney Local Health District - Campbelltown Hospital, Gordon Sussman Clinical Research Inc., McMaster University, Ottawa Allergy Research Corp, Clinique Specialisée en Allergie de la Capitale (CSAC), University Hospital in Pilsen (Fakultni nemocnice Plzen), Johannes Gutenberg University Mainz, HZRM Hamophilia Center Rhein Main, Charité - Universitätsmedizin Berlin, Goethe University Frankfurt - Faculty of Medicine, Semmelweis University, Barzilai University Medical Center, Tel Aviv Sourasky Medical Center, Azienda Ospedaliero – Universitaria Policlinico – Vittorio Emanuele, Spitalul Clinic Municipal Cluj, La Paz Institute for Health Research (IdiPAZ), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Investigación Sanitaria La Fe de Valencia - University Hospital, Institute for Asthma and Allergy, AARA Research Center, Bernstein Clinical Research Center. LLC, Allergy, Asthma and Immunology Center (Tulsa), Clinical Research Center of Alabama, Virginia Commonwealth University (VCU), School of Medicine, Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Allergy & Asthma Medical Group, Medical Research of Arizona, Independent, University of California, San Diego (UCSD) - School of Medicine, University of California, San Diego (UCSD) - School of Medicine, CSL Behring - Germany, CSL Behring - Germany, CSL Behring, CSL Behring, CSL Behring and affiliation not provided to SSRN
Downloads 4 (617,492)

Abstract:

Loading...

C1-Esterase Inhibitor Protein, HAEGARDA, Hereditary Angioedema, Subcutaneous, Long-Term, Prophylaxis, Safety